Inflammatory Breast Cancer at Stage T4dN2aM0 – Efficacy of Neoadjuvant Therapy Based: A Case Report
DOI:
https://doi.org/10.12775/JEHS.2026.88.69528Keywords
Inflammatory breast cancer, Trastuzumab, Neoadjuvant therapy, BRCA1 gene, Post-mastectomy radiotherapy, HER2-positive breast cancerAbstract
A case of a 64-year-old female patient diagnosed with left-sided inflammatory breast cancer at stage T4dN2aM0 was described. Histopathological examination revealed grade 3 invasive ductal carcinoma, negative for hormonal receptor expression (ER−, PR−), with HER2 overexpression (3+) and a high Ki-67 proliferation index (85%). Metastatic involvement of the axillary lymph nodes was present.
Neoadjuvant therapy was administered, resulting in a partial clinical response. Subsequently, a modified radical mastectomy according to the Madden technique was performed. Postoperative histopathological assessment demonstrated no residual carcinoma within the breast (ypT0); however, metastatic involvement was confirmed in 5 lymph nodes (ypN2a). Adjuvant treatment included trastuzumab and radiotherapy.
During follow-up, no evidence of local recurrence or distant metastases was observed. Extended genetic testing did not identify mutations associated with hereditary cancer predisposition.
References
1. Mamouch F, Berrada N, Aoullay Z, et al. Inflammatory Breast Cancer: A Literature Review. World J Oncol. 2018 Nov;9(5-6):129-135. doi: 10.14740/wjon1161. Epub 2018 Nov 23. PMID: 30524636; PMCID: PMC6279456
2. Jagsi R, Mason G, Overmoyer BA, et al. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res Treat. 2022 Apr;192(2):235-243. doi: 10.1007/s10549-021-06434-x. Epub 2022 Jan 1. Erratum in: Breast Cancer Res Treat. 2022 Apr;192(2):245-247. doi: 10.1007/s10549-022-06534-2. PMID: 34973083; PMCID: PMC8926970
3. Takahashi Y, Sridhar N, Iwase T, et al. Inflammatory breast cancer, best practice in the community setting. NPJ Breast Cancer. 2025 Jun 7;11(1):52. doi: 10.1038/s41523-025-00765-4. PMID: 40483266; PMCID: PMC12145426
4. Chippa V, Barazi H. Inflammatory Breast Cancer. 2023 Apr 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 33231994
5. Seth A, Slama EM. Delayed Diagnosis of Inflammatory Breast Cancer Presenting as Acute Mastitis in a Patient One Month Postpartum. Am Surg. 2024 Jul;90(7):1925-1927. doi: 10.1177/00031348241241736. Epub 2024 Mar 24. PMID: 38523415
6. Grela-Wojewoda A, Püsküllüoğlu M, Sas-Korczyńska B, et al. Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population. Cancers (Basel). 2022 Jul 10;14(14):3353. doi: 10.3390/cancers14143353. PMID: 35884413; PMCID: PMC9313458
7. Bachir B, Anouti S, Abi Jaoude J, et al. Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab. Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):135-142. doi: 10.1016/j.ijrobp.2021.12.159. Epub 2022 Jan 2. PMID: 34986381
8. Hashmi AA, Mahboob R, Khan SM, et al. Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers. BMC Res Notes. 2018 Aug 13;11(1):574. doi: 10.1186/s13104-018-3677-y. PMID: 30103802; PMCID: PMC6090780
9. Fan Y, Wang Y, He L, et al. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival. ESMO Open. 2021 Aug;6(4):100232. doi: 10.1016/j.esmoop.2021.100232. Epub 2021 Aug 13. PMID: 34392135; PMCID: PMC8371219
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sandra Czyż, Wiktoria Marszał
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 38
Number of citations: 0
